I guess the volume of trades speaks for itself
I cant remember who said it but the value here is the different revenue streams that can be generated.
Company could make $5-$10M in licencing fees alone for the next couple of years. This would be on top of what we already have.
So many options and the guys at the helm are doing such a great job in over achieving and under estimating.
Cheers
- Forums
- ASX - By Stock
- BIG
- Ann: FY17 Cash Revenue Guidance Update
Ann: FY17 Cash Revenue Guidance Update, page-81
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add BIG (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online